troglitazone has been researched along with Angina Pectoris, Variant in 1 studies
Troglitazone: A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity.
Angina Pectoris, Variant: A clinical syndrome characterized by the development of CHEST PAIN at rest with concomitant transient ST segment elevation in the ELECTROCARDIOGRAM, but with preserved exercise capacity.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Murakami, T | 1 |
| Mizuno, S | 1 |
| Ohsato, K | 1 |
| Moriuchi, I | 1 |
| Arai, Y | 1 |
| Nio, Y | 1 |
| Kaku, B | 1 |
| Takahashi, Y | 1 |
| Ohnaka, M | 1 |
1 other study available for troglitazone and Angina Pectoris, Variant
| Article | Year |
|---|---|
Effects of troglitazone on frequency of coronary vasospastic-induced angina pectoris in patients with diabetes mellitus.
Topics: Angina Pectoris, Variant; Chromans; Diabetic Angiopathies; Endothelium, Vascular; Humans; Insulin Re | 1999 |